


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A method for the treatment of dry eye ~~and other disorders requiring the wetting of the eye~~ which comprises topically administering to the eye of a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound formula (I)



(I)

wherein:

Z^1, Z^2 independently = H, F, Br, Cl, F, or C_{1-3} alkyl;

$Y = CH-(CH_2)_n$ or $CH-O$;

$n = 0-3$;

$A = CH$ or N , provided that when $Y = CH-O$ then $A = CH$;

$A^2 = CH$ or N ;

$X = (CH_2)_n \cdot Y^2$ or $(CH_2)_n \cdot Y^3 (CH_2)_n \cdot Y^2$;

$X^2 = H, OR^5, C_{1-6}$ alkyl, $C(O)OR^6$, or $C(O)N(R^7)H$;

$n' = 2-6$;

$n'' = 2-4$;

$Y^2 = O, S$, or NH

$Y^3 = O$ or S ;

$R^1 = H$, or $(C(R^3)(R^4))X^2$; and

$R^2, R^3, R^4, R^5, R^6, R^7$ independently = H or C_{1-6} alkyl.

2. (original) The method of Claim 1 wherein

$Z^1, Z^2 = H$;

$Y = CH-O$;

A = CH;

X = (CH₂)_nY²;

X² = H or C(O)OR⁶;

n' = 2-4;

Y² = O or NH; and

R², R³, R⁴, R⁶ independently = H or C₁₋₄ alkyl.

3. (original) The method of Claim 2 wherein

A² = CH;

R¹ = (C(R³)(R⁴))X²

R², R⁶ independently = H or C₁₋₄ alkyl; and

R³, R⁴ independently = H or methyl.

4. (original) The method of Claim 1 wherein the compound of formula (I) is selected from the group consisting of

6-[3-[4-(diphenylmethoxy)piperidino]propylamino][1,2,4]triazolol[1,5,b]-pyridazine;

6-[3-[4-(diphenylmethoxy)piperidino]propylamino]-2-methyl[1,2,4]-triazolo[1,5,b]pyridazine;

2-[6-[3-[4-(diphenylmethoxy)piperidino]propylamino]imidazo[1,2,b]-pyridazin-2-yl]-2-methylpropionic acid;

2-[6-[3-[4-(diphenylmethoxy)piperidino]propylamino]imidazo[1,2,b]-pyridazin-2-yl]-2-methylpropionic acid dihydrate; and

2-[6-[3-[4-(diphenylmethoxy)piperidino]propoxy]imidazo[1,2,b]pyridazin-2-yl]-2-methylpropionic acid.

5. (original) The method of Claim 1 wherein the pharmaceutically effective amount of the compound of formula (I) in the composition is 0.001 – 1.0% (w/w).

6. (currently amended) The method of Claim 1 wherein the dry eye and other disorders requiring the wetting of the eye is symptoms of dry eye associated with refractive surgery.